Skip to main content
. Author manuscript; available in PMC: 2017 Jan 1.
Published in final edited form as: Biomaterials. 2015 Sep 28;74:231–244. doi: 10.1016/j.biomaterials.2015.09.031

Figure 4. Vaccination with 4TO7 PMVs protein transferred simultaneously with GPI-HER-2, GPI-IL-12, and GPI-B7-1 protects mice against challenge with HER-2 expressing tumor cells.

Figure 4

(A) Immunization of mice with 4TO7 PMVs protein transferred with GPI-HER-2 confers protection against experimental metastasis of HER-2-expressing tumor cells. Groups of mice (n = 5) were vaccinated and boosted on day 14 with 25 μg protein transferred PMVs i.v and then challenged 7 days post boost with HER-2-transfected 4TO7 tumor cells i.v. to induce metastasis in the lungs. Mice were sacrificed day 15 post challenge and metastasis of 4TO7-HER-2 cells to the lungs were analyzed by counting the number of 6-thioguanine resistant cells after 8 days of selection. (B) Immunization of mice with 4TO7 PMVs protein transferred with GPI-HER-2 confers protection against D2F2/E2 tumor cells. Groups of BALB/c mice (n = 5) were vaccinated and boosted with 25 μg of protein transferred 4TO7 PMVs s.c. on day 14 and then challenged s.c. with 2 × 105 D2F2/E2 (HER-2 positive) tumor cells. Protein transferred PMVs expressed similar levels of HER-2 at 0.034 μg HER-2/μg PMV. Tumor incidence and (C) tumor area were measured. Tumor free mice from (GPI-HER-2+GPI-IL-12+GPI-B7-1)-4TO7 group were then rechallenged 65 days post boost with either (D) 2 × 105 D2F2 (HER-2 negative) cells or (E) 2 × 105 4TO7 (HER-2 negative) cells. Tumor area in each mouse was measured. (Statistical analysis: (A) Two-Way ANOVA – Tukey’s multiple comparisons test; ** p < 0.01).